賽升藥業(300485.SZ)擬斥1億元參設生命科創基金
格隆匯8月15日丨賽升藥業(300485.SZ)公佈,為推動北京市生物醫藥和健康產業的發展壯大,實現資源共享、優勢互補及合作共贏,同時聚焦符合北京發展方向的項目,篩選擁有高端硬技術原始創新、國際或國內領先的基礎、前沿及交叉科學研究等重大科學發現或科技成果,公司擬計劃使用1億元自有資金參與投資設立生命科學原始創新基金(以工商管理部門最終核准登記的名稱為準,“生命科創基金”)。
該基金為北京市科技創新基金的子基金。北京市科技創新基金是由北京市政府主導的股權投資母基金,基金總規模為300億元,投資階段分為原始創新、成果轉化及“高精尖”產業,將重點投資光電科技、新一代信息技術、納米技術、戰略性新材料、新能源、生物醫藥、智能製造、現代農業、現代交通業、節能環保、腦認知與類腦智能、量子計算與量子通信、大數據和人工智能等14個領域。
生命科學原始創新基金(以工商登記為準)基金規模:基金擬定總規模為人民幣10億元(以最終實際募集為準)。基金首期出資總金額為5億元。合作模式:充分利用現有的平台資源進行合作,共同支持北京市生物醫藥產業快速發展。
公司此次參與設立生命科創基金旨在藉助專業的投資團隊、投資渠道及強大的資源整合能力,充分結合公司的行業經驗、技術判斷與資源優勢,積極尋求生物醫藥產業優秀企業的投資機會,依據公司發展戰略路徑進行戰略投資項目選擇,有效實現公司戰略擴張計劃及資本增值。此次合作是公司戰略擴張創新模式的再次探索,有助於公司加速佈局覆蓋大健康產業相關領域,加強核心能力建設促進戰略目標的持續推進與快速發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.